Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

Otto Metzger-Filho, E. De Azambuja, Marion Procter, Magalie Krieguer, Ian Smith, Jose Baselga, David Cameron, Michael Untch, Christian Jackisch, Richard Bell, Luca Gianni, Aron Goldhirsch, Martine Piccart, R. D. Gelber

Research output: Contribution to journalArticle

Abstract

This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe the duration of trastuzumab-based regimens in the metastatic setting for patients previously treated with adjuvant trastuzumab. The first objective included 187 patients treated with adjuvant trastuzumab and diagnosed with distant recurrence at 4-year median follow-up. The second objective included data from questionnaires sent to investigators retreating patients with trastuzumab upon distant recurrence: 144 of 156 questionnaires were returned (93 %), and 90 patients were selected based on available clinical information and consent for subsequent studies. There was no statistically significant relationship between TDRI following 1 year of adjuvant trastuzumab and OS from distant recurrence: hazard ratio 0.991, p = 0.46. The median OS from distant recurrence was numerically longer among patients with a TDRI of ≥12 months (n = 103) than

Original languageEnglish
Pages (from-to)127-132
Number of pages6
JournalBreast Cancer Research and Treatment
Volume155
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Recurrence
Therapeutics
Survival
Trastuzumab
Research Personnel
Surveys and Questionnaires

Keywords

  • Breast cancer
  • Disease-free survival
  • HER2+

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval : the HERA trial experience. / Metzger-Filho, Otto; De Azambuja, E.; Procter, Marion; Krieguer, Magalie; Smith, Ian; Baselga, Jose; Cameron, David; Untch, Michael; Jackisch, Christian; Bell, Richard; Gianni, Luca; Goldhirsch, Aron; Piccart, Martine; Gelber, R. D.

In: Breast Cancer Research and Treatment, Vol. 155, No. 1, 01.01.2016, p. 127-132.

Research output: Contribution to journalArticle

Metzger-Filho, O, De Azambuja, E, Procter, M, Krieguer, M, Smith, I, Baselga, J, Cameron, D, Untch, M, Jackisch, C, Bell, R, Gianni, L, Goldhirsch, A, Piccart, M & Gelber, RD 2016, 'Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience', Breast Cancer Research and Treatment, vol. 155, no. 1, pp. 127-132. https://doi.org/10.1007/s10549-015-3656-0
Metzger-Filho, Otto ; De Azambuja, E. ; Procter, Marion ; Krieguer, Magalie ; Smith, Ian ; Baselga, Jose ; Cameron, David ; Untch, Michael ; Jackisch, Christian ; Bell, Richard ; Gianni, Luca ; Goldhirsch, Aron ; Piccart, Martine ; Gelber, R. D. / Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval : the HERA trial experience. In: Breast Cancer Research and Treatment. 2016 ; Vol. 155, No. 1. pp. 127-132.
@article{f4c4985d9f7a450580bc0a679156a78e,
title = "Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience",
abstract = "This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe the duration of trastuzumab-based regimens in the metastatic setting for patients previously treated with adjuvant trastuzumab. The first objective included 187 patients treated with adjuvant trastuzumab and diagnosed with distant recurrence at 4-year median follow-up. The second objective included data from questionnaires sent to investigators retreating patients with trastuzumab upon distant recurrence: 144 of 156 questionnaires were returned (93 {\%}), and 90 patients were selected based on available clinical information and consent for subsequent studies. There was no statistically significant relationship between TDRI following 1 year of adjuvant trastuzumab and OS from distant recurrence: hazard ratio 0.991, p = 0.46. The median OS from distant recurrence was numerically longer among patients with a TDRI of ≥12 months (n = 103) than",
keywords = "Breast cancer, Disease-free survival, HER2+",
author = "Otto Metzger-Filho and {De Azambuja}, E. and Marion Procter and Magalie Krieguer and Ian Smith and Jose Baselga and David Cameron and Michael Untch and Christian Jackisch and Richard Bell and Luca Gianni and Aron Goldhirsch and Martine Piccart and Gelber, {R. D.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s10549-015-3656-0",
language = "English",
volume = "155",
pages = "127--132",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval

T2 - the HERA trial experience

AU - Metzger-Filho, Otto

AU - De Azambuja, E.

AU - Procter, Marion

AU - Krieguer, Magalie

AU - Smith, Ian

AU - Baselga, Jose

AU - Cameron, David

AU - Untch, Michael

AU - Jackisch, Christian

AU - Bell, Richard

AU - Gianni, Luca

AU - Goldhirsch, Aron

AU - Piccart, Martine

AU - Gelber, R. D.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe the duration of trastuzumab-based regimens in the metastatic setting for patients previously treated with adjuvant trastuzumab. The first objective included 187 patients treated with adjuvant trastuzumab and diagnosed with distant recurrence at 4-year median follow-up. The second objective included data from questionnaires sent to investigators retreating patients with trastuzumab upon distant recurrence: 144 of 156 questionnaires were returned (93 %), and 90 patients were selected based on available clinical information and consent for subsequent studies. There was no statistically significant relationship between TDRI following 1 year of adjuvant trastuzumab and OS from distant recurrence: hazard ratio 0.991, p = 0.46. The median OS from distant recurrence was numerically longer among patients with a TDRI of ≥12 months (n = 103) than

AB - This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe the duration of trastuzumab-based regimens in the metastatic setting for patients previously treated with adjuvant trastuzumab. The first objective included 187 patients treated with adjuvant trastuzumab and diagnosed with distant recurrence at 4-year median follow-up. The second objective included data from questionnaires sent to investigators retreating patients with trastuzumab upon distant recurrence: 144 of 156 questionnaires were returned (93 %), and 90 patients were selected based on available clinical information and consent for subsequent studies. There was no statistically significant relationship between TDRI following 1 year of adjuvant trastuzumab and OS from distant recurrence: hazard ratio 0.991, p = 0.46. The median OS from distant recurrence was numerically longer among patients with a TDRI of ≥12 months (n = 103) than

KW - Breast cancer

KW - Disease-free survival

KW - HER2+

UR - http://www.scopus.com/inward/record.url?scp=84953357758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953357758&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3656-0

DO - 10.1007/s10549-015-3656-0

M3 - Article

VL - 155

SP - 127

EP - 132

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -